These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35468270)

  • 21. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
    Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
    Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and Validation of a Novel Dual-Drop-off ddPCR Assay for the Simultaneous Detection of Ten Hotspots
    Stergiopoulou D; Smilkou S; Georgoulias V; Kaklamanis L; Lianidou E; Markou A
    Anal Chem; 2023 Sep; 95(37):14068-14076. PubMed ID: 37681347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of genetic alterations differs in advanced breast cancer between metastatic sites.
    Grote I; Poppe A; Lehmann U; Christgen M; Kreipe H; Bartels S
    Genes Chromosomes Cancer; 2024 Jan; 63(1):e23199. PubMed ID: 37672607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
    Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accurate Detection of Multiple Tumor Mutations in Formalin-Fixed Paraffin-Embedded Tissues by Coupling Sequence Artifacts Elimination and Mutation Enrichment With MeltArray.
    Lan Y; Xu B; Xi Y; Luo Y; Guo X; Huang Z; Luo D; Zhu A; He P; Li C; Huang Q; Li Q
    Lab Invest; 2024 Feb; 104(2):100300. PubMed ID: 38042496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
    Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
    BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
    Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C
    Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
    Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
    Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
    Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
    Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic PIK3CA mutations in lobular breast cancer progression.
    Christgen M; Noskowicz M; Schipper E; Christgen H; Heil C; Krech T; Länger F; Kreipe H; Lehmann U
    Genes Chromosomes Cancer; 2013 Jan; 52(1):69-80. PubMed ID: 22997091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIK3CA mutation associates with improved outcome in breast cancer.
    Kalinsky K; Jacks LM; Heguy A; Patil S; Drobnjak M; Bhanot UK; Hedvat CV; Traina TA; Solit D; Gerald W; Moynahan ME
    Clin Cancer Res; 2009 Aug; 15(16):5049-59. PubMed ID: 19671852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
    Jacot W; Dalenc F; Lopez-Crapez E; Chaltiel L; Durigova A; Gros N; Lozano N; Lacaze JL; Pouderoux S; Gladieff L; Romieu G; Roché H; Filleron T; Lamy PJ
    Breast Cancer Res Treat; 2019 Oct; 177(3):659-667. PubMed ID: 31297647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
    Deng L; Zhu X; Sun Y; Wang J; Zhong X; Li J; Hu M; Zheng H
    Cancer Res Treat; 2019 Jan; 51(1):128-140. PubMed ID: 29540052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers.
    Schleifman EB; Desai R; Spoerke JM; Xiao Y; Wong C; Abbas I; O'Brien C; Patel R; Sumiyoshi T; Fu L; Tam RN; Koeppen H; Wilson TR; Raja R; Hampton GM; Lackner MR
    PLoS One; 2014; 9(2):e88401. PubMed ID: 24520381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
    Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
    Del Re M; Crucitta S; Lorenzini G; De Angelis C; Diodati L; Cavallero D; Bargagna I; Cinacchi P; Fratini B; Salvadori B; Ghilli M; Roncella M; Fontana A; Danesi R; Cucchiara F
    Pharmacol Res; 2021 Jan; 163():105241. PubMed ID: 33049397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
    Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
    BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.